Naslov
The role of AREDS like nutritional supplements in the prevention of age related macular degeneration
(Salopek Rabatić, Jasminka ; Kaštelan, Snježana ; Rabatić, Leon ; Pili, Kristijan)

Autori
Salopek Rabatić, Jasminka ; Kaštelan, Snježana ; Rabatić, Leon ; Pili, Kristijan

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
3rd Optometry Conference of Central and South-Eastern Europe. / - , 2016, 32-32

Skup
3rd Optometry Conference of Central and South-Eastern Europe.

Mjesto i datum
Split, Hrvatska, 14.04.2016. - 16.04.2016

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Age related macular degeneration, AREDS like - nutritional supplements, prevention, visual acuity

Sažetak
Age-related Macular Degeneration (AMD) is a progressive disorder associated with central vision loss and is the leading cause of visual impairment and blindness in people over the age of 60. Dry, atrophic, or non-exudative, AMD is the most common form. Although the underlying cause of AMD is unknown, risk factors have been defined and include age greater than 50, Caucasian race, nutrition, smoking, atherosclerotic vascular disease, genetics, and sunlight exposure. At this time, there is no known cure for AMD. Patients not receiving treatment have demonstrated a loss of VA at 6 months of at least 0.8 lines and up to 1.5 lines. Multiple studies have suggested that manipulation of nutritional factors can play a significant role in slowing the onset or limiting the effects of AMD. The Age-Related Eye Disease Study (AREDS I), sponsored by the National Eye Institute, demonstrated that high levels of antioxidants and zinc were able to reduce the risk of development of advanced AMD by approximately 25%. In 2004, the Lutein Antioxidant Supplementation Trial (LAST) demonstrated that nutritional supplementation with lutein or lutein together with antioxidants, vitamins, and minerals improved visual function and symptoms in patients with atrophic age-related macular degeneration. Publication of AREDS II in 2013. came with new supporting evidence. The primary objective of this case study was to measure the change from baseline in visual function – Best-Corrected Visual Acuity (BCVA) via the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, contrast sensitivity, central 10 degree visual fields and retinal imaging (angiograms and photographs) at 6 months in subjects with atrophic (dry) age-related macular degeneration treated with a targeted AREDS –Like nutritional supplement. Methods & patients 5 mixed gender patients with a mean age of 70.3 +/- 7.8 years were enrolled in two urban hospital retina centers practice and received standard of care with a AREDS-like formulation of a nutritional supplement. Results were compared to a placebo cohort constructed from the literature that was matched for inclusion and exclusion criteria. A paired t-test was used to test a null hypothesis and a two-sided alpha level of 0.05 was used to determine statistical significance. Results Presented are results of subjects receiving the nutritional supplement demonstrating stabilization or improvement of BCVA at 6 months. The results are providing strong evidence that the treatment being studied produces an improvement in VA. Conclusion Treatment with AREDS-like nutritional supplement increased VA above the expected baseline decrease in the majority of patients in this population with dry macular degeneration (published literature). Our results agree with the TOZAL, LAST, AREDS II and CARMIS studies. However, patients will require supplementation for longer than 6 months to effect changes in additional visual parameters.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA